Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Type 2 diabetes mellitus~2. GFR\<60 ml/min~3. HbA1c \>=7.0% to \<= 10%~4. Age \>= 18 years~5. BMI \<=45 kg/m2~6. Signed and dated written informed consent~Exclusion criteria:~1. Myocardial infarction, stroke or TIA within 3 months prior to informed consent~2. Renal impairment requiring dialysis~3. Bariatric surgery~4. Impaired hepatic function~5. Treatment with glitazones, GLP-1 analogues, DPP-4 inhibitors~6. Treatment with anti-obesity drugs~7. Treatment with SU, glinides and metformin 8 weeks prior to informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Linagliptin (Type: EXPERIMENTAL): 52 weeks treatment
- Placebo (Type: PLACEBO_COMPARATOR): First 12 weeks of treatment
- Glimepiride (Type: ACTIVE_COMPARATOR): Placebo patients switch to glimepiride after 12 weeks (40 weeks treatment)

Based on this trial design, predict the completion outcome and termination type (if applicable).